A Pilot Study for Ilorasertib (ABT-348) in Patients With CDKN2A-deficient Advanced Solid Cancers: A Series of Individual Patient Cross-Over Studies With Growth Trajectory Assessment
Phase of Trial: Phase I
Latest Information Update: 10 Aug 2017
At a glance
- Drugs Ilorasertib (Primary)
- Indications Solid tumours
- Focus Proof of concept; Therapeutic Use
- 07 Aug 2017 Planned End Date changed from 1 Oct 2017 to 1 Oct 2018.
- 07 Aug 2017 Planned primary completion date changed from 1 Oct 2017 to 1 Jun 2018.
- 06 Jun 2017 Results of a pharmaco-kinetics/dynamics evaluation from NCT02540876 and NCT01110486 trials presented at the 53rd Annual Meeting of the American Society of Clinical Oncology